431 Results

People

  1. Motzer
    Motzer
  2. Voss
    Voss
  3. Feldman
    Feldman
  4. Antonescu
    Antonescu
  5. Hakimi
    Hakimi
  6. Patil
    Patil
  7. Abou-Alfa
    Abou-Alfa
  8. DeMatteo
    DeMatteo
  9. Ginsberg
    Ginsberg
  10. Reidy
    Reidy

Groups

  1. Department of Medicine (315)
  2. Solid Tumor Oncology Division (288)
  3. Genitourinary Oncology Service (198)
  4. Surgery (60)
  5. GSK Faculty (47)
  6. Department of Pathology and Laboratory Medicine (44)
  7. Gastrointestinal Oncology Service (41)
  8. Radiology, Department of (38)
  9. Survivorship Research (34)
  10. Tow Center for Developmental Oncology (TCDO) (33)
  1. "sunitinib"
Formats
  1. Journal Article (391)
  2. Review (21)
  3. Editorial (5)
  4. Research Letter (4)
  5. Book Section (3)
  6. Correspondence (3)
  7. Guidelines (3)
  8. Miscellaneous (1)
Groups
  1. Department of Medicine (315)
  2. Solid Tumor Oncology Division (288)
  3. Genitourinary Oncology Service (198)
  4. Surgery (60)
  5. GSK Faculty (47)
  6. Department of Pathology and Laboratory Medicine (44)

More Groups

People
  1. Robert Motzer (159)
  2. Martin Voss (24)
  3. Darren Feldman (23)
  4. Robert Maki (20)
  5. Chung-Han Lee (17)
  6. Cristina Antonescu (17)

More People

Years
  1. 2025 (7)
  2. 2024 (18)
  3. 2023 (18)
  4. 2022 (18)
  5. 2021 (13)
  6. 2020 (18)

More Years

Publications
  1. Journal of Clinical Oncology (19)
  2. Clinical Cancer Research (18)
  3. European Urology (18)
  4. Journal of the National Comprehensive Cancer Network (17)
  5. Cancer (14)
  6. European Journal of Cancer (13)

More Publications

Publishers
  1. Elsevier Inc. (69)
  2. Elsevier Science, Inc. (38)
  3. Springer (31)
  4. Wiley Blackwell (30)
  5. Oxford University Press (29)
  6. Nature Publishing Group (27)

More Publishers

Results (431)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: Final analysis of the phase III JAVELIN Renal 101 trial
    Journal Article

    Choueiri, T. K.; Penkov, K.; Uemura, H.; Campbell, M. T.; Pal, S.; Kollmannsberger, C.; Lee, J. L.; Venugopal, B.; van den Eertwegh, A. J. M.; Negrier, S.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Biomarker analyses from the phase III randomized CLEAR trial: Lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma
    Journal Article

    Motzer, R. J.; Porta, C.; Eto, M.; Hutson, T. E.; Rha, S. Y.; Merchan, J. R.; Winquist, E.; Gurney, H.; Grünwald, V.; George, S.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • STELLAR-304: A phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma
    Journal Article

    Pal, S. K.; Powles, T.; Kanesvaran, R.; Molina-Cerrillo, J.; Feldman, D. R.; Barata, P.; Liu, M.; Bhatt, A.; Wang, Z.; Nandoskar, P.; more...
    Future Oncology (2025)

    Fulltext@MSK | Save
  • Gene expression of prostate-specific membrane antigen (FOLH1) in clear cell renal cell carcinoma predicts angiogenesis and response to tyrosine kinase inhibitors
    Journal Article

    Khaleel, S.; Perera, M.; Papa, N.; Kuo, F.; Golkaram, M.; Rappold, P.; Kotecha, R. R.; Coleman, J.; Russo, P.; Motzer, R.; more...
    Urologic Oncology: Seminars and Original Investigations (2025)

    Fulltext@MSK | Save
  • Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial
    Journal Article

    Grünwald, V.; McKay, R. R.; Buchler, T.; Eto, M.; Park, S. H.; Takagi, T.; Zanetta, S.; Keizman, D.; Suárez, C.; Négrier, S.; more...
    International Journal of Cancer (2025)

    Fulltext@MSK | Save
  • Vascular endothelial growth factor and programmed cell death-1 inhibition in bone sarcomas
    Editorial

    Reinhorn, D.; D’Angelo, S. P.
    Cancer (2025)

    Fulltext@MSK | Save
  • Sample site impacts RNA biomarkers for renal cell carcinoma
    Journal Article

    Eismann, L.; Xie, A. X.; Tang, C.; Knezevic, A.; Ostrovnaya, I.; Kuo, F.; Ari Hakimi, A.; Reznik, E.; Kotecha, R. R.
    European Urology (2025)

    Fulltext@MSK | Save
  • The INSIGHT study: A randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations
    Journal Article

    George, S.; Blay, J. Y.; Chi, P.; Jones, R. L.; Serrano, C.; Somaiah, N.; Gelderblom, H.; Zalcberg, J. R.; Reichmann, W.; Sprott, K.; more...
    Future Oncology (2024)

    Fulltext@MSK | Save
  • Multiscale mapping of transcriptomic signatures for cardiotoxic drugs
    Journal Article

    Hansen, J.; Xiong, Y.; Siddiq, M. M.; Dhanan, P.; Hu, B.; Shewale, B.; Yadaw, A. S.; Jayaraman, G.; Tolentino, R. E.; Chen, Y.; more...
    Nature Communications (2024)

    Fulltext@MSK | Save
  • Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214
    Journal Article

    Mantia, C. M.; Jegede, O. A.; Plimack, E. R.; Powles, T.; Motzer, R. J.; Tannir, N. M.; Lee, C. H.; Tomita, Y.; Voss, M. H.; Choueiri, T. K.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save